Skip to content

Treatment of acute post-Anserin bursitis with topical injection of corticosteroids and high-level laser therapy

Comparison of the effectiveness of topical corticosteroid injection and high-level laser therapy in patients with acute post-Anserin bursitis(PAB)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20151123025202N19
Enrollment
60
Registered
2021-12-28
Start date
2022-01-21
Completion date
Unknown
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pes anserine bursitis knee. Rheumatoid bursitis, knee

Interventions

Intervention 1: Intervention group: One group will undergo high-level laser therapy. For this purpose, gallium aluminum arsenide diode laser (model 4 cube-laser-K) with a wavelength of 1064 nm, an out

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Diagnosis of PAB according to clinical criteria and imaging by a specialist physician At least 3 months after diagnosis Age 18-65 years Minimum pain intensity according to VAS> 3

Exclusion criteria

Exclusion criteria: Comorbidity with other diseases such as: advanced osteoarthritis, infection, neurological and motor diseases (stroke, Parkinson's, myopathies, neuropathies, ....), other systemic diseases such as rheumatoid arthritis and heart disease History of recent knee surgery or trauma Treatment with corticosteroid now or during the last 4 months

Design outcomes

Primary

MeasureTime frame
Pes anserine bursitis thickness changes. Timepoint: Before treatment, one month later, and three months after treatment. Method of measurement: sonography.;Pain severity of knee. Timepoint: Before treatment, one month later, and three months after treatment. Method of measurement: By Visual Analogue Scale.

Secondary

MeasureTime frame
Patients Quality of life. Timepoint: Before treatment, one month and three months after starting treatment. Method of measurement: With SF-12 Quality of Life Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbbas Moradi

Hamedan University of Medical Sciences

a.moradi@umsha.ac.ir+98 81 3838 0557

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026